Amryt boost as rival Amicus pulls EB drug
Irish group Amryt has become the frontrunner in the race to find a treatment for epidermolysis bullosa (EB), known as butterfly disease, which causes skin in mainly young patients to blister at the slightest touch.
Rival Amicus Therapeutics, which had been ahead of Amryt, has pulled its drug after it failed to meet certain targets in a phase iii trial. Amryt, which started its trial earlier this year, is expected to report interim data in the first half of 2018.
Goodbody analyst Andrew Young said Amryt’s AP101 drug was a gel that only needs to be applied when dressings are changed every three or four days, as recommended for EB patients.
Amicus’s water-based cream required patients to change dressings daily and this may have been a factor in its failure.